Amyloid‐β Inspired Short Peptide Amphiphile Facilitates Synthesis of Silver Nanoparticles as Potential Antibacterial Agents. (28th June 2022)

• Record Type: Journal Article
• Authors: Tripathi, Satyendra K.; Kesharwani, Khushboo; Kaul, Grace; Akhir, Abdul; Saxena, Deepanshi; Singh, Ramesh; Mishra, Narendra K.; Pandey, Archna; Chopra, Sidharth; Joshi, Khashti B.
• Is Part Of: ChemMedChem. Volume 17:Number 15(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-06-28
• Subjects: Short peptide amphiphiles -- Phenylalanine -- Silver nanoparticles -- Antibacterial -- Self-assembly; Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.1002/cmdc.202200251
• Languages: English
• ISSNs: 1860-7179

Abstract

Abstract: An amyloid‐β inspired biocompatible short peptide amphiphile (sPA) molecule was used for controlled and targeted delivery of bioactive silver nanoparticles via transforming sPA nanostructures. Such sPA‐AgNPs hybrid structures can be further used to develop antibacterial materials to combat emerging bacterial resistance. Due to the excellent antibacterial activity of silver, the growth of clinically relevant bacteria was inhibited in the presence of AgNPs‐sPA hybrids. Bacterial tests demonstrated that the high biocompatibility and low cytotoxicity of the designed sPA allow it to work as a model drug delivery agent. It therefore shows great potential in locally addressing bacterial infections. The results of our study suggest that these nanodevices have the potential to trap and then engage in the facile delivery of their chemical payload at the target site, thereby working as potential delivery materials. This system has potential therapeutic value for the treatment of microbiota triggered progression of neurodegenerative diseases. Abstract : Silver payload ! An amyloid‐β inspired biocompatible short peptide amphiphile (sPA) was used for controlled and targeted delivery of bioactive silver nanoparticles. Such sPA‐AgNPs hybrid structures can be further used to develop antibacterial materials to combat emerging bacterial resistance. This approach has potential therapeutic value in the treatment of microbiota triggered progression of neurodegenerative diseases.